How much funding has Tacalyx raised?

Tacalyx has raised $28.1M in total funding, most recently a Extension Round.

Who are Tacalyx's investors?

Tacalyx's investors include Boehringer Ingelheim Venture Fund, Thuja Capital, Kurma Partners, Eurazeo, Creathor Ventures, High-Tech Grunderfonds.

Where is Tacalyx headquartered?

Tacalyx is headquartered in Berlin, Germany.

Tacalyx

Glycan excellence against cancer

Berlin, Germany · Founded 2019 · $28.1M raised

Biotech

Headquarters: Berlin
Employees: 11–50
Founded: 2019
Business Model: B2B

Website: tacalyx.com
Total Funding: $28.1M
Last Round: $13.0M Extension RoundApr 2026
Rounds: 2

About

Tacalyx is a Berlin-based biotech company founded in 2019 as a spin-out of the Max-Planck-Institute of Colloids and Interfaces (MPICI) in Potsdam, Germany. The company develops novel anticancer therapeutics targeting Tumor Associated Carbohydrate Antigens (TACAs) — carbohydrate structures highly expressed on tumor cells but not in healthy differentiated tissues. Tacalyx's pipeline includes antibody-drug conjugates (ADCs) and other immunotherapeutics targeting TACAs, with its lead TCX-201 programme advancing toward clinical trials after a €11 million funding round in April 2026. Tacalyx is backed by High-Tech Gründerfonds, Kurma Partners, Boehringer Ingelheim Venture Fund, Creathor Ventures, and Max-Planck-Innovation.

Summary

Tacalyx is a Biotech company based in Berlin, Germany, founded in 2019. It has raised $28.1M in total across 2 rounds, most recently a $13.0M Extension Round round in Apr 2026. Investors include Boehringer Ingelheim Venture Fund, Thuja Capital and Kurma Partners.

LinkedIn X (Twitter)